Sobi Announces Successful Completion of Class C Share Issuance and Repurchase Plan

Sobi Completes Class C Share Issuance and Repurchase

Svenska Orphan Biovitrum AB, widely known as Sobi®, has recently marked a significant milestone in its financial operations following a resolution passed during its Annual General Meeting on May 6, 2026. The meeting resulted in the successful issuance of redeemable and convertible class C shares, which aims to support Sobi's ongoing employee incentive programs.

Details of the Share Issuance

During the aforementioned meeting, the Board was granted the authority to initiate an acquisition offer directed at all existing class C shareholders for the company's repurchase plan. This strategic move, finalized on July 15, 2026, aligns with Sobi's objectives to ensure adequate resources for fulfilling its obligations under the All Employee Programme, a long-term incentive initiative designed for permanent employees.

Following this initiative, Svenska Handelsbanken AB stepped into the limelight. On August 31, 2026, it successfully subscribed to all 223,677 class C shares that were issued. This completion signifies not only the financial stability of Sobi but also its commitment to rewarding its employees through meaningful incentive structures. The total proceeds amassed from this issue amounted to SEK 122,732.80.

Implications of the Repurchase

With the successful acquisition of class C shares, Sobi's Board of Directors has indicated a plan to convert the repurchased shares into common stock. This conversion process is facilitated by provisions included in Sobi’s articles of incorporation, which aim to secure future availability of common shares for distribution to participants of the incentive program. Following the venture, Sobi's common shares will increase from 9,408,278 to 9,631,955, illustrating the company’s proactive approach in managing shareholdings and employee compensation.

At present, Sobi operates as a global biopharmaceutical company focused on addressing the unique needs of individuals facing rare diseases. With a workforce of approximately 2,000 employees across key regions including Europe, North America, the Middle East, and Asia, the company reported revenues of SEK 28 billion in the fiscal year 2025. These figures not only showcase Sobi's economic growth but also lay a robust foundation for its continuous innovation and service delivery in the healthcare sector.

Moreover, Sobi's commitment to engaging with its stakeholders, including shareholders and employees, through initiatives like these reaffirms its status in the Nasdaq Stockholm under the ticker symbol SOBI. For those interested in gaining more insight into Sobi and its operations, up-to-date information can be accessed on their official website or through their LinkedIn page.

In conclusion, the recent issuance and repurchase of class C shares underline Sobi's strategic aptitude in navigating financial markets and its ongoing dedication to fostering a motivated workforce equipped to make a difference in the lives of patients worldwide. As the company continues to innovate and expand its horizons, stakeholders remain optimistic about Sobi's trajectory in the biopharmaceutical industry.